Journals / Retina-Vitreus / 2016 / Cilt: 24 - Sayı: 2

The Effectiveness of Intravitreal Dexamethasone Implant in Macular Edema Related to Retinal Vein Occlusions

Retina Ven Tıkanıklığına Bağlı Makula Ödeminde İntravitreal Deksametazon İmplantın Etkinliği

Pages
151–156
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Medical therapy was adequate in patients with intraocular pressure rising and one patient underwent cataract surgery.Results: It is shown intravitreal dexamethasone implant is effective and safe in treatment of macular edema related to retinal vein occlusions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant in treatmant of macular edema related to retinal vein occlusions.Material and Methods: The charts of 38 patients treated with intravitreal dexamethasone implant due to macular edema related to retinal vein occlusions between 1 May 2013 and 1 September 2014 in Trakya University Ophthalmology Department were retrospectively evaluated.Results: In 23 patients with branch retinal vein occlusion (BRVO), while 15 had central retinal vein occlusion (CRVO).
📊
Key Findings & Data:Mean age was 66.47±9.48; 17 men (%44.7) and 21 women (%55.3) patients were available.
💡
Conclusion & Impact:Medical therapy was adequate in patients with intraocular pressure rising and one patient underwent cataract surgery.Results: It is shown intravitreal dexamethasone implant is effective and safe in treatment of macular edema related to retinal vein occlusions.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant in treatmant of macular edema related to retinal vein occlusions.Material and Methods: The charts of 38 patients treated with intravitreal dexamethasone implant due to macular edema related to retinal vein occlusions between 1 May 2013 and 1 September 2014 in Trakya University Ophthalmology Department were retrospectively evaluated.Results: In 23 patients with branch retinal vein occlusion (BRVO), while 15 had central retinal vein occlusion (CRVO). Mean age was 66.47±9.48; 17 men (%44.7) and 21 women (%55.3) patients were available. Postinjection best corrected visual acuity (BCVA) was better than preinjection at each visit in BRVO patients (pİ0.05). Postinjection central macular thickness (CMT) was thinner than preinjection and statistically significant at postinjection 1 day, 1 week, 1 month, 2 month, 3 month and 6 month (pİ0.05). BCVA increased statistically significant to preinjection at postinjection 1 week, 1 month and 2 month in CRVO patients (pİ0.05). BCVA was reduced at postinjection 3 months, gradually increased going from 4 to 6 months also showed no statistically significant difference compared to preinjection (pı0.05). CMT decreased incipiently postinjection 1 day to postinjection 2 month and thickness reduction was statistically significant at postinjection 1 day, 1 week, 1month and 2 month (pİ0.05). Medical therapy was adequate in patients with intraocular pressure rising and one patient underwent cataract surgery.Results: It is shown intravitreal dexamethasone implant is effective and safe in treatment of macular edema related to retinal vein occlusions.

Özet

Amaç: Retina ven tıkanıklığına (RVT) bağlı makula ödemi tedavisinde intravitreal deksametazon implantın etkinliğini ve güvenilirliğini değerlendirmek.Gereç ve Yöntem: Trakya Üniversitesi Göz Hastalıkları Anabilim Dalı'nda 1 Mayıs 2013 ile 1 Eylül 2014 tarihleri arasında RVT'ye bağlı makula ödemi tedavisi için intravitreal deksametazon implant uygulanan 38 hastanın dosyaları retrospektif olarak değerlendirildi.Bulgular: Olguların 23'ünde retina ven dal tıkanıklığı (RVDT), 15'inde ise retina ven kök tıkanıklığı (RVKT) vardı. Yaş ortalaması 66.47±9.48 olup, 17 erkek (%44.7), 21 kadın (%55.3) olgu mevcuttu. RVDT olgularında enjeksiyon sonrası tüm kontrollerde en iyi düzeltilmiş görme keskinliği (EİDGK) enjeksiyon öncesine göre daha iyiydi ve istatistiksel olarak anlamlıydı (pİ0.05). Santral makula kalınlığı (SMK), enjeksiyon sonrası 1. gün, 1. hafta, 1. ay, 2. ay, 3. ay ve 6. ayda enjeksiyon öncesine göre istatistiksel olarak anlamlı derecede ince bulundu (pİ0.05). RVKT olgularında EİDGK, enjeksiyon sonrası 1. hafta, 1. ay ve 2. ayda enjeksiyon öncesine göre istatistiksel olarak anlamlı derecede artmış bulundu (pİ0.05). Enjeksiyon sonrası 3. ayda azalan en iyi düzeltilmiş görme keskinliği, 4 ile 6 ay arasında giderek artsa da enjeksiyon öncesine göre istatistiksel olarak anlamlı farklılık görülmedi (pı0.05). Santral makula kalınlığı median değerleri enjeksiyon sonrası 1. günden başlayarak, enjeksiyon sonrası 2. aya kadar azaldı ve kalınlık değişimi enjeksiyon sonrası 1. gün, 1. hafta, 1. ay ve 2. ayda enjeksiyon öncesine göre istatistiksel olarak anlamlıydı (pİ0.05). Göz içi basıncı yükselen olgularda medikal tedavi yeterli olurken, katarakt gelişen bir olguya cerrahi yapıldı.Sonuç: RVT'ye bağlı makula ödemi tedavisinde intravitreal deksametazon implantın etkin ve güvenilir olduğu görülmüştür.

🔖

Cite This Article

ÖZELCE, R., GÜRLÜ, V., ÖZAL, S. A., GÜÇLÜ, H., ESGİN, H. (2016). The Effectiveness of Intravitreal Dexamethasone Implant in Macular Edema Related to Retinal Vein Occlusions. Retina-Vitreus, Cilt: 24 - Sayı: 2, 151–156. https://ajindex.com/articles/307885

References (9)

  1. Klein R, Moss SE, Meuer SM et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008;126:513-8.
  2. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-31.
  3. Scott IU, Ip MS, VanVeldhuisen PC et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
  4. Campochiaro PA, Heier JS, Feiner L et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12 e1. Haller JA, Bandello F, Belfort R et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46 e3. Duvall B, Kershner R. Ophthalmic Medications and Pharmacology. United States of America: SLACK incorporated; 2006:53-62.
  5. Ip MS, Scott IU, VanVeldhuisen PC et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.
  6. Bezatis A, Spital G, Hohn F et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up the SOLO study. Acta Ophthalmol 2013;91:e340-7. Capone A, Jr., Singer MA, Dodwell DG et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014;34:342-51.
  7. Querques L, Querques G, Lattanzio R et al. Repeated intravitreal dexamet- hasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmologica 2013;229:21-5. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-90.
  8. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50.
  9. Mayer WJ, Wolf A, Kernt M et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 2013;27